EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

RNA editing: Expanding the potential of RNA therapeutics

Brian J Booth, Sami Nourreddine, Dhruva Katrekar, Yiannis Savva, Debojit Bose, Thomas J Long, David J Huss, Prashant Mali

Molecular Therapy · 2023-06 · 31 (6) · 1533-1549

DOI: 10.1016/j.ymthe.2023.01.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2023-06. Verfasst von Brian J Booth und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shape Therapeutics, Seattle, WA, USA. Hauptthemen laut MEDLINE: RNA, COVID-19. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA therapeutics have had a tremendous impact on medicine, recently exemplified by the rapid development and deployment of mRNA vaccines to combat the COVID-19 pandemic. In addition, RNA-targeting drugs have been developed for diseases with significant unmet medical needs through selective mRNA knockdown or modulation of pre-mRNA splicing. Recently, RNA editing, particularly antisense RNA-guided adenosine deaminase acting on RNA (ADAR)-based programmable A-to-I editing, has emerged as a powerful tool to manipulate RNA to enable correction of disease-causing mutations and modulate gene expression and protein function. Beyond correcting pathogenic mutations, the technology is particularly well suited for therapeutic applications that require a transient pharmacodynamic effect, such as the treatment of acute pain, obesity, viral infection, and inflammation, where it would be undesirable to introduce permanent alterations to the genome. Furthermore, transient modulation of protein function, such as altering the active sites of enzymes or the interface of protein-protein interactions, opens the door to therapeutic avenues ranging from regenerative medicine to oncology. These emerging RNA-editing-based toolsets are poised to broadly impact biotechnology and therapeutic applications. Here, we review the emerging field of therapeutic RNA editing, highlight recent laboratory advancements, and discuss the key challenges on the path to clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNACOVID-19HumansRNA-Binding ProteinsRNA EditingPandemicsAdenosine Deaminase

Stichwörter der Autor:innen

ADARADAR1ADAR2ASORNA editingRNA therapeuticsgene therapyprecision medicine

Substanzen

RNARNA-Binding ProteinsAdenosine Deaminase

Autor:innen und Institutionen

  • Shape Therapeutics, Seattle, WA, USA.
  • Department of Bioengineering, University of California San Diego, La Jolla, CA, USA.
  • Shape Therapeutics, Seattle, WA, USA. Electronic address: david@shapetx.com.
  • Department of Bioengineering, University of California San Diego, La Jolla, CA, USA. Electronic address: pmali@ucsd.edu.

Förderung

  • NIH HHS
  • NCI NIH HHS
  • NIGMS NIH HHS
  • California Institute for Regenerative Medicine
  • DOD
  • NIH
  • University of California, San Diego

Zitieren

APA

Booth, B. J., Nourreddine, S., Katrekar, D., Savva, Y., Bose, D., Long, T. J., Huss, D. J., & Mali, P. (2023). RNA editing: Expanding the potential of RNA therapeutics. Molecular Therapy, 31(6), 1533-1549. https://doi.org/10.1016/j.ymthe.2023.01.005

Vancouver

Booth BJ, Nourreddine S, Katrekar D, Savva Y, Bose D, Long TJ, et al. RNA editing: Expanding the potential of RNA therapeutics. Molecular Therapy. 2023;31(6):1533-1549. doi:10.1016/j.ymthe.2023.01.005

BibTeX
@article{Booth2023,
  author = {Booth, Brian J and Nourreddine, Sami and Katrekar, Dhruva and Savva, Yiannis and Bose, Debojit and Long, Thomas J and Huss, David J and Mali, Prashant},
  title = {RNA editing: Expanding the potential of RNA therapeutics},
  journal = {Molecular Therapy},
  year = {2023},
  volume = {31},
  number = {6},
  pages = {1533--1549},
  doi = {10.1016/j.ymthe.2023.01.005}
}
Kostenlos starten →